Analysts Set Heron Therapeutics, Inc. (NASDAQ:HRTX) Price Target at $4.50

Heron Therapeutics, Inc. (NASDAQ:HRTX) has earned an average rating of “Hold” from the five research firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $4.50.

A number of research firms have weighed in on HRTX. Zacks Research upgraded Heron Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 7th. Needham & Company LLC decreased their target price on shares of Heron Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Heron Therapeutics in a report on Tuesday, November 4th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Heron Therapeutics in a report on Wednesday, October 8th. Finally, Wall Street Zen downgraded Heron Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, August 9th.

Heron Therapeutics Stock Performance

Shares of HRTX stock opened at $1.27 on Friday. The company has a debt-to-equity ratio of 19.89, a quick ratio of 1.78 and a current ratio of 2.56. The firm has a market capitalization of $232.87 million, a price-to-earnings ratio of -14.11 and a beta of 1.34. Heron Therapeutics has a one year low of $1.00 and a one year high of $2.68. The company has a 50 day moving average price of $1.20 and a 200 day moving average price of $1.55.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.03). The business had revenue of $38.21 million for the quarter, compared to the consensus estimate of $39.03 million. Sell-side analysts anticipate that Heron Therapeutics will post -0.13 EPS for the current year.

Institutional Investors Weigh In On Heron Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Nuveen LLC acquired a new position in Heron Therapeutics during the first quarter valued at $691,000. Congress Park Capital LLC grew its stake in Heron Therapeutics by 11.4% during the 2nd quarter. Congress Park Capital LLC now owns 2,268,249 shares of the biotechnology company’s stock valued at $4,695,000 after acquiring an additional 232,632 shares in the last quarter. Jefferies Financial Group Inc. purchased a new position in Heron Therapeutics during the 1st quarter valued at about $710,000. Informed Momentum Co LLC acquired a new position in shares of Heron Therapeutics in the 1st quarter valued at about $768,000. Finally, AIGH Capital Management LLC lifted its position in shares of Heron Therapeutics by 8.3% in the second quarter. AIGH Capital Management LLC now owns 3,009,257 shares of the biotechnology company’s stock worth $6,229,000 after purchasing an additional 231,057 shares in the last quarter. 80.01% of the stock is currently owned by hedge funds and other institutional investors.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.